$1 billion in profit would be pretty unrealistic.
Even $1 billion in sales revenue is beyond my most optimistic expectations at this stage.
I know Dendreon is not a perfect comparison but it's useful as a rough guide.
They just announced their quarterly sales for Provenge at $85.5m (up on analyst expectations).
Annualised, that's US$342m
DNDN is currently running a COS at around 70%, so annual earnings on that basis is around US$103m.
Their market cap at the moment is US$846, putting them on a P/E ratio of 8.2 (which is low for a biotech).
PRR could realistically achieve annual sales revenue for Cvac (Ovarian cancer only) of around $250 - 300m.
Their estimate COS is in the range of 25-30%
Annualised earnings extrapolate to around $200m
Pick a P/E ratio and multiply those earnings for estimated market cap.
Caveat: All the above obviously depends on successful trial results and commercial approvals from the FDA, EU etc.
- Forums
- ASX - By Stock
- IMM
- prr's cvac - one billion dollars per year?
prr's cvac - one billion dollars per year?, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
39.5¢ |
Change
0.005(1.28%) |
Mkt cap ! $573.7M |
Open | High | Low | Value | Volume |
38.5¢ | 40.0¢ | 38.5¢ | $1.022M | 2.599M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 17394 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 60247 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 17394 | 0.390 |
6 | 90082 | 0.385 |
9 | 81777 | 0.380 |
2 | 33070 | 0.375 |
5 | 111756 | 0.370 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 60247 | 1 |
0.400 | 43444 | 4 |
0.405 | 183170 | 3 |
0.410 | 238354 | 9 |
0.415 | 211366 | 9 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |